Home › Releases › Tsingke Biotech Undergoes Quality Audit at Chengdu...
Releases

Tsingke Biotech Undergoes Quality Audit at Chengdu Facility

Tsingke Biotech Undergoes Quality Audit at Chengdu Facility

Sichuan Kelun-Biotech Biopharmaceutical conducted a comprehensive on-site audit of Tsingke’s Chengdu manufacturing site this October. The review scrutinized core quality management protocols, ranging from raw material traceability to the integrity of computerized systems, as the company scales its integrated AI-driven molecular manufacturing operations.

The audit prioritized four critical areas: raw material tracking, equipment maintenance, data management, and the handling of biological samples. Auditors examined the entire lifecycle of materials, verifying that record-keeping connects specific inputs to final products. Equipment oversight was assessed through qualification logs, calibration certificates, and maintenance history to ensure consistent production standards.

Digital oversight formed a significant portion of the inspection, specifically regarding the security and validation of systems like Core-System and U8 Cloud. Tsingke utilized this review to demonstrate how standardized workflows support its broader 'Gene Factory' model. By integrating digital technologies with molecular manufacturing, the company aims to move beyond isolated production steps, instead optimizing the entire manufacturing chain. These established quality controls serve as the technical foundation for applying artificial intelligence to process monitoring and future manufacturing scalability.

Share:TelegramXFacebook

Read Also

Comments (0)

Leave a comment

No comments yet. Be the first!